Description: CytRx Corporation, a biopharmaceutical company, engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides albumin companion diagnostic for cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Home Page: www.cytrx.com
11726 San Vicente Boulevard
Los Angeles,
CA
90049
United States
Phone:
310-826-5648
Officers
| Name | Title |
|---|---|
| Mr. John Y. Caloz | CFO, Treasurer & Sr. VP |
| Dr. Stephen Snowdy Ph.D. | Chief Exec. Officer |
| Molly Carey Poarch | Global & U.S. Head of Corp. Communications |
| Ms. Molly Painter | Pres of USA and Head of Launch & Commercial Operations |
| Terri Stevens | Chief Bus. Officer |
| Ms. Cristina Newman | Corp. Sec. |
| Dr. Felix Kratz Ph.D. | Sr. VP, Drug Devel. |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.7133 |
| Price-to-Sales TTM: | 34.4758 |
| IPO Date: | 1986-11-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |